Olanzapine use in adolescent anorexia nervosa
Several case reports and open label trials describe olanzapine in the treatment of anorexia nervosa (AN). We report 5 adolescents with AN who received olanzapine in addition to psychotherapy for their eating disorder. Body mass index (BMI) of each case increased while on olanzapine. At doses of 5 mg per day and above, patients reported decreased anxiety around eating, improved sleep, and decreased rumination about food and body concerns. Morning sedation was the most commonly reported adverse effect. Olanzapine appeared to be useful in addition to psychotherapy for these adolescents. This report augments a limited literature on the treatment of this disorder, and an almost nonexistent literature specific to pharmacotherapy for adolescents with AN.
Key wordsOlanzapine anorexia nervosa adolescents
- 1.Walsh B.T., Kaplan A.S, Attia E., Carter J., Devlin M.J., Olmsted M., Pike K.M., Woodside B., Parides M.: Fluoxetine vs. Placebo to prevent relapse in anorexia nervosa: Primary outcome of drug on time to relapse in 93 weight restored subjects. Paper presented at the Eating Disorders Research Society, Toronto, September, 2005.Google Scholar
- 5.Frank G.K., Kaye W.H., Weltzin T.E., Perel J., Moss H., McConaha C, Pollice C: Altered response to meta-chlorophenylpiperazine in anorexia nervosa: support for a persistent alteration of serotonin activity after short-term weight restoration. Int. J. Eat. Disord., 30, 57–68, 2001.PubMedCrossRefGoogle Scholar
- 7.Attia E., Kaplan A.S., Schroeder L., Federici A., Staab R.: Atypical antipsychotic medication in anorexia nervosa. Paper presented at the Eating Disorders Research Society, Toronto, September, 2005.Google Scholar
- 12.Mondraty N, Birmingham C.L., Touyz S., Sundakov V., Chapman L., Beaumont P.: Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Aust. Psychiatry, 13, 72–75, 2005.Google Scholar